TCM
VKTX icon

Tekla Capital Management’s Viking Therapeutics VKTX Stock Holding History

Tekla Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-114,016
Closed -$946K – 199
2019
Q2 		$946K Hold
114,016
– – 0.04% 166
2019
Q1 		$1.13M Buy
114,016
+57,008
+100% +$477K 0.05% 156
2018
Q4 		$436K Buy
+57,008
New +$682K 0.02% 190

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Tekla Capital Management's VKTX Position: Q3 2019 in Review

Tekla Capital Management sold out of Viking Therapeutics (VKTX) in Q3 2019, closing a stake of 114,016 shares — an estimated $946K sold.

Tekla Capital Management first reported a position in VKTX in Q4 2018 and held it in 3 quarters. The position peaked at $1.13M in Q1 2019. 144 funds tracked by Wall St. Rank hold VKTX as of Q3 2019.

  • Tekla Capital Management reported no remaining Viking Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Tekla Capital Management sold 114,016 Viking Therapeutics shares in Q3 2019, an estimated $946K.
  • Tekla Capital Management first reported a position in Viking Therapeutics in Q4 2018 and held it in 3 quarters.
  • Tekla Capital Management's Viking Therapeutics position peaked at $1.13M in Q1 2019.
  • 144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2019.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.